Long Liang, Yan Qingzi, Xiao Can, Liu Xiang, Yan Yi
Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, Hunan Province, China.
Department of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan Province, China.
Medicine (Baltimore). 2025 Aug 29;104(35):e43862. doi: 10.1097/MD.0000000000043862.
Cryptococcal meningitis is caused by Cryptococcus neoformans and Cryptococcus gattii, predominantly affects immunocompromised host. Resistance to amphotericin B poses therapeutic challenges, especially in immunocompetent individuals, where evidence is scarce.
This study reports a case of an old immunocompetent male diagnosed with amphotericin B-resistant C neoformans meningitis.
Amphotericin B-resistant C neoformans meningitis.
Treatment failure occurred with both induction regimens (amphotericin B deoxycholate/fluconazole for 14 days followed by fluconazole/flucytosine for 29 days), then used salvage therapy combining amphotericin B colloidal dispersion (ABCD) in this amphotericin B-resistant C neoformans meningitis.
Successful salvage therapy with ABCD/flucytosine was achieved in a case of amphotericin B-resistant C neoformans meningitis. However, the patient ultimately succumbed to multidrug-resistant Klebsiella pneumoniae meningitis secondary to prolonged dexamethasone use for ABCD infusion reaction prophylaxis, which induced significant immunosuppression.
ABCD is a feasible alternative treatment for amphotericin B-resistant C neoformans meningitis. During prolonged ABCD therapy, pharmacists must implement pharmaceutical care to ensure medication safety and mitigate adverse effects, thereby preventing treatment discontinuation or treatment failure.
新型隐球菌性脑膜炎由新生隐球菌和格特隐球菌引起,主要影响免疫功能低下的宿主。对两性霉素B耐药带来了治疗挑战,尤其是在免疫功能正常个体中,相关证据较少。
本研究报告了一例老年免疫功能正常男性被诊断为对两性霉素B耐药的新生隐球菌性脑膜炎的病例。
对两性霉素B耐药的新生隐球菌性脑膜炎。
两种诱导治疗方案(两性霉素B脱氧胆酸盐/氟康唑治疗14天,随后氟康唑/氟胞嘧啶治疗29天)均治疗失败,随后在该例对两性霉素B耐药的新生隐球菌性脑膜炎中采用了两性霉素B胶体分散体(ABCD)联合挽救治疗。
在一例对两性霉素B耐药的新生隐球菌性脑膜炎中,采用ABCD/氟胞嘧啶成功进行了挽救治疗。然而,患者最终因长期使用地塞米松预防ABCD输注反应导致多药耐药肺炎克雷伯菌脑膜炎而死亡,这导致了显著的免疫抑制。
ABCD是对两性霉素B耐药的新生隐球菌性脑膜炎的一种可行替代治疗方法。在长期ABCD治疗期间,药师必须实施药学监护以确保用药安全并减轻不良反应,从而防止治疗中断或治疗失败。